Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy.
In an ideal world, photodynamic therapy (PDT) of abnormal tissue would reliably spare the surrounding normal tissue. Normal tissue responses set the limits for light and drug dosimetry. The threshold fluence for necrosis (TFN) was measured in normal skin following intravenous infusion with a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD-MA) Verteporin as a function of drug dose (0.25-2.0 mg/kg), wavelength of irradiation (458 and 690 nm) and time interval (0-5 h) between drug administration and irradiation. The BPD-MA levels were measured in plasma and skin tissue to elucidate the relationship between TFN, drug kinetics and biodistribution. The PDT response of normal skin was highly reproducible. The TFN for 458 and 690 nm wavelengths was nearly identical and the estimated quantum efficiency for skin response was equal at these two wavelengths. Skin phototoxicity, quantified in terms of 1/TFN, closely correlated with the plasma pharmacokinetics rather than the tissue pharmacokinetics and was quadratically dependent on the plasma drug concentration regardless of the administered drug dose or time interval between drug and light exposure. This study strongly suggests that noninvasive measurements of the circulating drug level at the time of light treatment will be important for setting optimal light dosimetry for PDT with liposomal BPD-MA, a vascular photosensitizer.
Lin
G C
GC
Wellman Laboratories of Photomedicine, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston 02114, USA.
Tsoukas
M L
ML
Lee
M S
MS
González
S
S
Vibhagool
C
C
Anderson
R R
RR
Kollias
N
N
D000818:Animals; D004337:Drug Carriers; D005260:Female; D006801:Humans; D008081:Liposomes; D008954:Models, Biological; D009336:Necrosis; D010778:Photochemotherapy / Q000009:adverse effects* / Q000379:methods*; D017319:Photosensitizing Agents / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D011166:Porphyrins / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D011817:Rabbits; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D014018:Tissue Distribution
D004337:Drug Carriers; D008081:Liposomes; D017319:Photosensitizing Agents; D011166:Porphyrins; C504224:benzoporphyrin D